LLY vs GILD
By Alex · Tickerpine
Eli Lilly and Company vs Gilead Sciences, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | GILD |
|---|---|---|
| Price | $1,443.50 | $168.08 |
| Market cap | $1.29T | $208.48B |
| P/E ratio | 46.9 | — |
| ROE | 86.02% | -22.45% |
| Profit margin | 31.90% | -12.46% |
| Revenue growth | 38.60% | 6.80% |
| Dividend yield | 0.48% | 1.95% |
| Beta | 0.39 | 0.37 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs GILD in plain English
- LLY is the bigger company — about 6.2× the market cap of GILD.
- LLY earns a higher return on equity (86% vs -22%).
- LLY is growing revenue faster (39% vs 7%).
- GILD has the higher dividend yield (1.95% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
GILD return calculator
See what $1,000 in Gilead Sciences, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.